JNCE

Jounce Therapeutics, Inc. Common Stock

Delisted

JNCE was delisted on the 3rd of May, 2023.

113 hedge funds and large institutions have $285M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

more funds holding in top 10

Funds holding in top 10:

less call options, than puts

Call options by funds: $ | Put options by funds: $

less funds holding

Funds holding:

less capital invested

Capital invested by funds: $ → $

17% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 41

50% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 20

Holders
113
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$390K
Puts
$410K
Net Calls
Net Calls Change

Top Sellers

1 -$11.4M
2 -$9.17M
3 -$2.82M
4
Goldman Sachs
Goldman Sachs
New York
-$2.23M
5
Barclays
Barclays
United Kingdom
-$1.76M
Name Holding Trade Value Shares
Change
Change in
Stake
26
$2.22M
27
$2.15M
28
$1.93M
29
$1.88M
30
$1.87M
31
$1.72M
32
$1.52M
33
$1.16M
34
$1.02M
35
$984K
36
$958K
37
$865K
38
$861K
39
$838K
40
$726K
41
$620K
42
$549K
43
$495K
44
$488K
45
$442K
46
$437K
47
$422K
48
$397K
49
$361K
50
$347K